1
|
Ouagazzal AM, Tepper JM, Creese I. Reducing gene expression in the brain via antisense methods. ACTA ACUST UNITED AC 2008; Chapter 5:Unit 5.4. [PMID: 18428503 DOI: 10.1002/0471142301.ns0504s00] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This unit presents protocols that employ antisense oligodeoxynucleotides to reduce expression of target proteins in the brain. These oligonucleotides are generally designed to inhibit synthesis of a specific protein by hybridization to its mRNA. Because oligonucleotides show very poor penetration into the central nervous system (CNS) after systemic administration, they are either injected into the cerebrospinal fluid (CSF) or infused directly into the brain parenchyma. In this unit, the procedure most commonly used for delivering oligonucleotides continuously into CSF is outlined. In addition, a procedure is described for continuous infusion of oligonucleotides into a specific brain region, using the substantia nigra as an example.
Collapse
Affiliation(s)
- A M Ouagazzal
- United Medical and Dental Schools, Guy's Hospital, London, UK
| | | | | |
Collapse
|
2
|
Van Oekelen D, Luyten WHML, Leysen JE. Ten years of antisense inhibition of brain G-protein-coupled receptor function. BRAIN RESEARCH. BRAIN RESEARCH REVIEWS 2003; 42:123-42. [PMID: 12738054 DOI: 10.1016/s0165-0173(03)00153-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Antisense oligonucleotides (AOs) are widely used as tools for inhibiting gene expression in the mammalian central nervous system. Successful gene suppression has been reported for different targets such as neurotransmitter receptors, neuropeptides, ion channels, trophic factors, cytokines, transporters, and others. This illustrates their potential for studying the expression and function of a wide range of proteins. AOs may even find therapeutic applications and provide an attractive strategy for intervention in diseases of the central nervous system (CNS). However, a lack of effectiveness and/or specificity could be a major drawback for research or clinical applications. Here we provide a critical overview of the literature from the past decade on AOs for the study of G-protein-coupled receptors (GPCRs). The following aspects will be considered: mechanisms by which AOs exert their effects, types of animal model system used, detection of antisense action, effects of AO design and delivery characteristics, non-antisense effects and toxicological properties, controls used in antisense studies to assess specificity, and our results (failures and successes). Although the start codon of the mRNA is the most popular region (46%) to target by AOs, targeting the coding region of GPCRs is almost as common (41%). Moreover, AOs directed to the coding region of the GPCR mRNA induce the highest reductions in receptor levels. To resist degradation by nucleases, the modified phosphorothioate AO (S-AO) is the most widely used and effective oligonucleotide. However, the end-capped phosphorothioate AOs (ECS-AOs) are increasingly used due to possible toxic and non-specific effects of the S-AO. Other parameters affecting the activity of a GPCR-targeting AO are the length (mostly an 18-, 20- or 21-mer) and the GC-content (mostly varying from 30 to 80%). Interestingly, one-third of the AOs successfully targeting GPCRs possess a GC/AT ratio of 61-70%. AO-induced reductions in GPCR expression levels and function range typically from 21 to 40% and 41 to 50%, respectively. In contrast to many antisense reviews, we therefore conclude that the functional activity of a GPCR after AO treatment correlates mostly with the density of the target receptors (maximum factor 2). However, AOs are no simple tools for experimental use in vivo. Despite successful results in GPCR research, no general guidelines exist for designing a GPCR-targeting AO or, in general, for setting up a GPCR antisense experiment. It seems that the correct choice of a GPCR targeting AO can only be ascertained empirically. This disadvantage of antisense approaches results mostly from incomplete knowledge about the internalisation and mechanism of action of AOs. Together with non-specific effects of AOs and the difficulties of assessing target specificity, this makes the use of AOs a complex approach from which conclusions must be drawn with caution. Further antisense research has to be carried out to ensure the adequate use of AOs for studying GPCR function and to develop antisense as a valuable therapeutic modality.
Collapse
Affiliation(s)
- Dirk Van Oekelen
- Discovery Research, Janssen Research Foundation, B-2340 Beerse, Belgium
| | | | | |
Collapse
|
3
|
Murphy D, Wells S. In vivo gene transfer studies on the regulation and function of the vasopressin and oxytocin genes. J Neuroendocrinol 2003; 15:109-25. [PMID: 12535153 DOI: 10.1046/j.1365-2826.2003.00964.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Novel genes can be introduced into the germline of rats and mice by microinjecting fertilized one-cell eggs with fragments of cloned DNA. A gene sequence can thus be studied within the physiological integrity of the resulting transgenic animals, without any prior knowledge of its regulation and function. These technologies have been used to elucidate the mechanisms by which the expression of the two genes in the locus that codes for the neuropeptides vasopressin and oxytocin is confined to, and regulated physiologically within, specific groups of neurones in the hypothalamus. A number of groups have described transgenes, derived from racine, murine and bovine sources, in both rat and mouse hosts, that mimic the appropriate expression of the endogenous vasopressin and genes in magnocellular neurones (MCNs) of the supraoptic and paraventricular nuclei. However, despite considerable effort, a full description of the cis-acting sequences mediating the regulation of the vasopressin-oxytocin locus remains elusive. Two general conclusions have nonetheless been reached. First, that the proximal promoters of both genes are unable to confer any cell-specific regulatory controls. Second, that sequences downstream of the promoter, within the structural gene and/or the intergenic region that separates the two genes, are crucial for appropriate expression. Despite these limitations, sufficient knowledge has been garnered to specifically direct the expression of reporter genes to vasopressin and oxytocin MCNs. Further, it has been shown that reporter proteins can be directed to the regulated secretory pathway, from where they are subject to appropriate physiological release. The use of MCN expression vectors will thus enable the study of the physiology of these neurones through the targeted expression of biologically active molecules. However, the germline transgenic approach has a number of limitations involving the interpretation of phenotypes, as well as the large cost, labour and time demands. High-throughput somatic gene transfer techniques, principally involving the stereotaxic injection of hypothalamic neuronal groups with replication-deficient adenoviral vectors, are now being developed that obviate these difficulties, and which enable the robust, long-lasting expression of biologically active proteins in vasopressin and oxytocin MCNs.
Collapse
Affiliation(s)
- D Murphy
- Molecular Neuroendocrinology Research Group, University of Bristol Research Centre for Neuroendocrinology, Bristol Royal Infirmary, Bristol, UK.
| | | |
Collapse
|
4
|
Anselmet A, Mayat E, Wietek S, Layer PG, Payrastre B, Massoulié J. Non-antisense cellular responses to oligonucleotides. FEBS Lett 2002; 510:175-80. [PMID: 11801249 DOI: 10.1016/s0014-5793(01)03248-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Oligonucleotides induce various cellular responses which are not due to the blockade of protein synthesis by an antisense mechanism. Oligonucleotides presenting double-stranded or G-quartet structures (ribo- or deoxyribonucleotides, phosphodiester or phosphorothioated) induce retraction of neurites and aggregation of chicken retinal cells within 10-20 h. This effect is reversible, non-toxic; it appears to require internalization and can be mimicked by treatment of the cells with an RGDS peptide. The oligonucleotides appear to trigger a cascade of intracellular events, affecting the adhesive properties of integrins. In addition, a subset of oligonucleotides induced platelet aggregation, probably through their interaction with membrane receptors. Recognition of these effects is important for the design and interpretation of antisense experiments.
Collapse
Affiliation(s)
- Alain Anselmet
- CNRS UMR 8544, Laboratoire de Neurobiologie, Ecole Normale Supérieure, Paris, France.
| | | | | | | | | | | |
Collapse
|
5
|
Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 2001; 81:1197-267. [PMID: 11427695 DOI: 10.1152/physrev.2001.81.3.1197] [Citation(s) in RCA: 238] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The hypothalamo-neurohypophysial system (HNS) is the major peptidergic neurosecretory system through which the brain controls peripheral physiology. The hormones vasopressin and oxytocin released from the HNS at the neurohypophysis serve homeostatic functions of water balance and reproduction. From a physiological viewpoint, the core question on the HNS has always been, "How is the rate of hormone production controlled?" Despite a clear description of the physiology, anatomy, cell biology, and biochemistry of the HNS gained over the last 100 years, this question has remained largely unanswered. However, recently, significant progress has been made through studies of gene identity and gene expression in the magnocellular neurons (MCNs) that constitute the HNS. These are keys to mechanisms and events that exist in the HNS. This review is an inventory of what we know about genes expressed in the HNS, about the regulation of their expression in response to physiological stimuli, and about their function. Genes relevant to the central question include receptors and signal transduction components that receive and process the message that the organism is in demand of a neurohypophysial hormone. The key players in gene regulatory events, the transcription factors, deserve special attention. They do not only control rates of hormone production at the level of the gene, but also determine the molecular make-up of the cell essential for appropriate development and physiological functioning. Finally, the HNS neurons are equipped with a machinery to produce and secrete hormones in a regulated manner. With the availability of several gene transfer approaches applicable to the HNS, it is anticipated that new insights will be obtained on how the HNS is able to respond to the physiological demands for its hormones.
Collapse
Affiliation(s)
- J P Burbach
- Rudolf Magnus Institute for Neurosciences, Section of Molecular Neuroscience, Department of Medical Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands.
| | | | | | | |
Collapse
|
6
|
Greenwood RS, Fan Z, McHugh R, Meeker R. Inhibition of hippocampal kindling by metabotropic glutamate receptor antisense oligonucleotides. Mol Cell Neurosci 2000; 16:233-43. [PMID: 10995550 DOI: 10.1006/mcne.2000.0862] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Recent work has shown that metabotropic glutamate receptors (mGluRs) increase in response to seizure activity and can contribute significantly to the expression and progression of partial seizures. Using the kindling model of temporal lobe seizures, we evaluated the ability of local hippocampal injections of mGluR1 antisense or mGluR3 antisense oligonucleotides to suppress receptor expression and alter hippocampal kindling. Daily antisense injections in the hippocampus resulted in a significant decrease in mGluR1 or mGluR2/3 immunoreactivity. Rats injected with mGluR3 antisense showed a brief suppression of afterdischarge duration when compared to matched rats injected with a nonsense-oligonucleotide. Rats injected with a mGluR1 antisense oligonucleotide had a dramatic suppression of the rate of seizure progression with no significant effect on afterdischarge duration. Suppression of mGluR1 synthesis by local antisense inhibition may provide a new therapeutic approach for the control of epileptogenesis.
Collapse
Affiliation(s)
- R S Greenwood
- Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, 27599, USA
| | | | | | | |
Collapse
|
7
|
Szklarczyk AW, Kaczmarek L. Brain as a unique antisense environment. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT 1999; 9:105-16. [PMID: 10192296 DOI: 10.1089/oli.1.1999.9.105] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
During the last few years, antisense oligodeoxyribonucleotides (asODN) have become a commonly used tool for blocking of gene expression in the mammalian central nervous system. Successful gene inhibition has been reported for such diverse targets as those encoding neurotransmitter receptors, neuropeptides, trophic factors, transcription factors, cytokines, transporters, ion channels, and others. This review presents a discussion of recent studies on ODN in the brain, with a focus on specific approaches taken by the researchers in this field and especially on peculiar features of this organ as a milieu for asODN action. It is concluded that from the presented literature survey no coherent view on how to rationally design ODN for brain studies has emerged.
Collapse
Affiliation(s)
- A W Szklarczyk
- Department of Molecular and Cellular Neurobiology, Nencki Institute, Warsaw, Poland
| | | |
Collapse
|
8
|
Kaufman GD, Shinder ME, Perachio AA. Correlation of Fos expression and circling asymmetry during gerbil vestibular compensation. Brain Res 1999; 817:246-55. [PMID: 9889379 DOI: 10.1016/s0006-8993(98)01284-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Vestibular compensation is a central nervous system process resulting in recovery of functional movement and control following a unilateral vestibular lesion. Small pressure injections of phosphorothioate 20mer oligonucleotides were used to probe the role of the Fos transcription protein during vestibular compensation in the gerbil brainstem. During isoflurane gas anesthesia, antisense probes against the c-fos mRNA sequence were injected into the medial vestibular and prepositus nuclei unilaterally prior to a unilateral surgical labyrinthectomy. Anionic dyes, which did not interact with the oligonucleotides, were used to mark the injection site and help determine the extent of diffusion. The antiFos oligonucleotide injections reduced Fos expression at the injection site in neurons which normally express Fos after the lesion, and also affected circling behavior induced by hemilabyrinthectomy. With both ipsilateral and contralateral medial vestibular and prepositus nuclei injections, less ipsilateral and more contralateral circling was noted in animals injected with antiFos injections as compared to non-injected controls. The degree of change in these behaviors was dependent upon the side of the injection. Histologically, antiFos injections reduced the number of Fos immunolabeled neurons around the injection site, and increased Fos expression contralaterally. The correlation of the number of neurons with Fos expression to turning behavior was stronger for contralateral versus ipsilateral turns, and for neurons in the caudal and ipsilateral sub-regions of the medial vestibular and prepositus nuclei. The results are discussed in terms of neuronal firing activity versus translational activity based on the asymmetrical expression of the Fos inducible transcription factor in the medial vestibular and prepositus nuclei. Although ubiquitous in the brain, transcription factors like Fos can serve localized and specific roles in sensory-specific adaptive stimuli. Antisense injections can be an effective procedure for localized intervention into complex physiological functions, e.g. vestibular compensation.
Collapse
Affiliation(s)
- G D Kaufman
- National Research Council Senior Associate, Life Sciences Division, Building 37, Mailcode SD3, NASA Johnson Space Center, Houston, TX 77058,
| | | | | |
Collapse
|
9
|
Skutella T, Probst JC, Renner U, Holsboer F, Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 1998; 85:795-805. [PMID: 9639273 DOI: 10.1016/s0306-4522(97)00682-9] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Two brain-derived corticotropin-releasing hormone receptors have been cloned, termed corticotropin-releasing hormone receptors type I and type 2. Antisense oligodeoxynucleotides targeted to the cloned rat and mouse corticotropin-releasing hormone receptors type I messenger RNA reduced the binding of the natural ligand of the corticotropin-releasing hormone receptors type I and also the release of adenocorticotrophic hormone in primary rat anterior pituitary cells and in clonal mouse pituitary cells (AtT-20) by up to 60% in an application time-dependent manner. Studies on intracellular uptake of fluorescence-labelled oligodeoxynucleotides indicated a cytoplasmic accumulation starting within two to four hours after application of oligodeoxynucleotides in vitro. In vivo, antisense oligodeoxynucleotides infused intra-cerebroventricularly reduced binding of radiolabelled corticotropin-releasing hormone receptors in central sites of the rat brain. Anxiety induced by i.c.v. administration of corticotropin-releasing hormone was attenuated by corticotropin-releasing hormone receptors type I antisense treatment as determined in the elevated plus maze and in the novel open field test. The corticotropin-releasing hormone-induced behavioural changes were absent in corticotropin-releasing hormone receptors type I antisense-pretreated animals. These results show that the selected antisense probes used were able to suppress corticotropin-releasing hormone receptors type I function in vitro as well as in vivo and suggest that the development of drugs blocking this specific receptor might lead to a novel class of anxiolytics.
Collapse
Affiliation(s)
- T Skutella
- Max Planck Institute of Psychiatry, Department of Neuroendocrinology, Munich, Germany
| | | | | | | | | |
Collapse
|
10
|
Robinson ES, Nutt DJ, Jackson HC, Hudson AL. Antisense oligonucleotides in psychopharmacology and behaviour: promises and pitfalls. J Psychopharmacol 1997; 11:259-69. [PMID: 9305419 DOI: 10.1177/026988119701100310] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Antisense oligonucleotides are used to study the expression and function of a diverse range of proteins. Areas for which antisense has been used for pharmacological investigation include receptors, neuropeptides and immediate early genes, particularly when specific ligands or markers are not yet available. Antisense oligonucleotides target a specific mRNA and block the expression of the protein by sequence specific hybridization. This technique has not only been shown to be a valuable pharmacological tool but also to have potential therapeutic applications. In this review we discuss the technology behind the technique including developments in methodology employed in antisense experiments. Although antisense provides a novel and highly specific tool, the reliability of the technique and many of the problems associated with antisense experiments are discussed. The main focus of this article is the use of antisense in psychopharmacology to investigate behavioural changes following antisense-mediated inhibition of the expression of specific brain proteins and receptors.
Collapse
Affiliation(s)
- E S Robinson
- Psychopharmacology Unit, School of Medical Sciences, Bristol, UK
| | | | | | | |
Collapse
|
11
|
Abstract
The use of antisense oligodeoxynucleotides, targeted to the transcripts encoding biologically active proteins in the nervous system, provides a novel and highly selective means to further our understanding of the function of these proteins. Recent studies of these agents also suggest the possibility of their being used therapeutically for a variety of diseases involving neuronal tissue. In this paper we review studies showing the in vitro and in vivo effects of antisense oligodeoxynucleotides as they relate to neurobiological functions. Particular attention is paid to the behavioral and biochemical effects of antisense oligodeoxynucleotides directed to the various subtypes of receptors for the neurotransmitter dopamine. An example is also provided showing the effects of a plasmid vector expressing an antisense RNA targeted to the calmodulin mRNAs in the PC12 pheochromocytoma cell line. The advantages of antisense oligodeoxynucleotides over traditional pharmacological treatments are assessed, and the advantages of using vectors encoding antisense RNA over the use of antisense oligodeoxynucleotides are also considered. We also describe the criteria that should be used in designing antisense oligodeoxynucleotides and several controls that should be employed to assure their specificity of action.
Collapse
Affiliation(s)
- B Weiss
- Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, USA
| | | | | |
Collapse
|
12
|
Abstract
Antisense oligodeoxynucleotides (ODN) offer the potential advantage to manipulate neuropeptide or neuropeptide receptor expression within the brain transiently and site-specifically, thus providing a tool for neuroendocrinological research into the physiological function of a particular neuropeptide system. In this study, various approaches are introduced which reveal that antisense ODN may exert acute, short-term effects on neuronal responsiveness to afferent stimuli, as well as long-term effects on neuropeptide/receptor protein availability in a given system depending on the duration of treatment. Short-term effects were seen in that oxytocin (OXT) and vasopressin (AVP) antisense ODN affected electrophysiological and secretory parameters of oxytocinergic and vasopressinergic neurons, respectively, as well as their ability to express the Fos protein in response to afferent stimulation a few hours after a single infusion into the hypothalamic supraoptic nucleus. In this study, two methodological approaches to study long-term effects of the antisense ODN are exemplified, in which antisense ODN directed against the mRNA coding for the neuropeptide itself or its receptor were used. The repeated infusion of corticotropin releasing hormone (CRH) antisense ODN into the paraventricular nucleus resulted in reduced immunoreactive CRH, but not AVP, in the external zone of the median eminence. Furthermore, in order to evaluate the receptor-mediated effects of CRH and AVP released locally within the paraventricular nucleus on adrenocorticotropin (ACTH) release from the pituitary, CRH receptor (and also AVP receptor) antisense ODN were repeatedly infused into the hypothalamic nuclei; this treatment resulted in an elevation of stimulated, but not basal, ACTH release into the blood. However, in addition to these obvious antisense effects, results are discussed which demonstrate sequence-unspecific effects of phosphorothioated ODN, suggesting that some of their mechanisms of action are not yet understood.
Collapse
Affiliation(s)
- I Neumann
- Max Planck Institute of Psychiatry, Munich, Germany
| |
Collapse
|
13
|
Rubenstein M, Mirochnik Y, Ray V, Guinan P. Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors. Med Oncol 1997; 14:131-6. [PMID: 9468034 DOI: 10.1007/bf02989639] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Antisense oligonucleotides (oligos) are now in clinical trials for the treatment of a variety of diseases. However, concern is sometimes expressed as to the toxicity of such compounds, particularly those with phosphorothioated backbones. We have previously reported (J. Surg. Oncol. 62, 194, 1996) our experience in treating nude mice bearing human PC-3 prostate tumors with phosphorothioated antisense oligos directed against mRNA encoding transforming growth factor-alpha (TGF-alpha) and the epidermal growth factor receptor (EGFR). This therapy resulted in a 75% (9/12) response rate for the intralesional treatment and a 100% (3/3) response rate for the systemic administration utilizing Alzet diffusion pumps. In the current study, athymic nude rats bearing orthotopically implanted LNCaP tumors, whose establishment was confirmed by the expression of human PSA, were implanted subcutaneously with Alzet diffusion pumps and treated systemically for 14 days with a total of 1 mg of each oligo (2 mg total). Controls consisted of five untreated rats similarly inoculated with LNCaP cells, but which did not receive antisense oligos. After 2 weeks the rats were sacrificed and serum samples were evaluated for BUN, creatinine, LDH and SGOT. Lungs, kidneys, livers, spleens and prostates were also removed for pathologic evaluation. There were no serum marker differences between groups nor was there histologic evidence of oligo toxicity seen in any evaluated tissue. Of interest was the observation that the livers and spleens, as well as prostates, of treated animals revealed mild lymphocytic infiltration compared to controls. We conclude that at this level of administration, there is no toxicity associated with 14-day oligo treatment.
Collapse
Affiliation(s)
- M Rubenstein
- Hektoen Institute for Medical Research, Department of Urology, Rush Presbyterian St. Lukes Medical Center, Chicago, Illinois 60612, USA
| | | | | | | |
Collapse
|
14
|
Abraham WC, Logan B, Thompson VL, Williams JM, Tate WP. Sequence-independent effects of phosphorothiolated oligonucleotides on synaptic transmission and excitability in the hippocampus in vivo. Neuropharmacology 1997; 36:345-52. [PMID: 9175613 DOI: 10.1016/s0028-3908(97)00013-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Antisense oligodeoxynucleotides (ODNs) have the potential to be a powerful tool for regulating gene expression and mRNA translation in spatially and temporally restricted domains. Prior to investigating the effects of antisense ODNs on hippocampal long-term potentiation, we investigated whether there are any non-specific effects of ODNs on perforant path synaptic transmission in the dentate gyrus of both pentobarbital-anaesthetized and awake, freely moving rats. Single injections of phosphorothioated antisense ODNs (4 nmol) to the immediate early gene zif/268 caused a rapid (within minutes) and long-lasting (>24 hr) profound depression of the perforant path evoked field potentials. This depressive effect was due to the phosphorothioate modification since a depression was not seen with unmodified antisense ODNs, relative to saline controls. Furthermore, the effect was not sequence-specific since modified sense ODNs caused the same degree of depression. The depression caused by the modified antisense ODNs was dose-dependent and specific to synaptic transmission, since antidromic population spikes elicited by mossy fibre stimulation were relatively unaffected compared to the orthodromic responses. A second unexpected side-effect of the modified ODNs was cellular hyperexcitability, such that bursts of epileptiform spikes in the EEG occurred both spontaneously and as a result of synaptic stimulation. While the mechanism of the synaptic depression remains unknown, these results indicate that phosphorothioate-modified ODNs exert profound non-specific effects on synaptic transmission in the hippocampus, that have the potential to seriously compromise any corresponding behavioural or electrophysiological studies.
Collapse
Affiliation(s)
- W C Abraham
- Department of Psychology, Neuroscience Research Centre, University of Otago, Dunedin, New Zealand.
| | | | | | | | | |
Collapse
|
15
|
Nicot A, Pfaff DW. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems. J Neurosci Methods 1997; 71:45-53. [PMID: 9125374 DOI: 10.1016/s0165-0270(96)00125-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Synthetic antisense oligodeoxynucleotides can inhibit the expression of a gene in a sequence-specific manner at the translational level. Their potential use to understand the role of neuropeptides or neurotransmitters in neuroendocrine and behavioral functions, and perhaps for therapeutic gene suppression, has become of great interest in neuroscience, especially in the cases of absence of available specific antagonists. Whether their action can be fully specific to the target gene and not only sequence-specific is, however, the main question about their application to brain studies. A number of factors such as the mode of action, specificity and chemistry of antisense molecules as well as the carrier vehicle and the time course of antisense treatment, must be carefully considered for the design and successful application of antisense oligonucleotides. Assay systems and controls must be chosen so as to ensure that the observed biological effects of antisense oligodeoxynucleotides do in fact reflect the result of a specific target gene inhibition. This article discusses these biochemical factors with the emphasis on the use of phosphodiester or phosphorothioate oligodeoxynucleotides in neuroendocrine or behavioral studies.
Collapse
Affiliation(s)
- A Nicot
- Laboratory of Neurobiology and Behavior, Rockefeller University, New York, NY 10021, USA
| | | |
Collapse
|
16
|
Wollnik F, Bihler S. Strain differences in the distribution of arginine-vasopressin- and neuropeptide Y-immunoreactive neurons in the suprachiasmatic nucleus of laboratory rats. Brain Res 1996; 724:191-9. [PMID: 8828568 DOI: 10.1016/0006-8993(96)00318-6] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We have studied the number of arginine-vasopressin (AVP)-immunoreactive (ir) somata and the area size of AVP- and neuropeptide Y (NPY)-ir fibers in the suprachiasmatic nuclei (SCN) of three strains of laboratory rats exhibiting a strong unimodal (ACI), a bimodal (BH), and a weak multimodal pattern (LEW) of wheel running activity. In all three strains, AVP-ir somata and fibers were located predominantly in the dorsomedial SCN. Significant strain-differences were found for the area size of AVP-ir fibers as well as for the number and density of AVP-ir somata. The total number of AVP-ir somata was significantly higher in strain ACI (2238 +/- 164) than in strains BH (1552 +/- 137) and LEW (1426 +/- 110), whereas the mean area of AVP-ir fibers was significantly larger in strain LEW (50779 +/- 2202 microns2) than in strains ACI (39034 +/- 2095 microns2) and BH (28052 +/- 1728 microns2). Consequently, the density of AVP-ir somata was significantly lower in LEW rats, which have a weak multimodal activity pattern, than in BH and ACI rats, which have a bimodal and unimodal activity pattern, respectively. These data suggest that AVP neurons may be part of SCN output pathways controlling circadian activity rhythms. NPY-ir fibers have been identified mainly in the ventral part of the SCN. The mean area of NPY-ir fibers was smallest in BH rats (26100 +/- 1822 microns2), which show a rather scattered activity onset, and larger in ACI (29934 +/- 2468 microns2) and LEW rats (31889 +/- 2728 microns2), which have rather precise activity onsets. The inbred strains ACI, BH, and LEW may prove to be suitable models to further study distinct neuronal substrates of the SCN functionally correlated with characteristic parameters of circadian rhythms.
Collapse
Affiliation(s)
- F Wollnik
- Dept. of Biology, University of Konstanz, Germany
| | | |
Collapse
|
17
|
Szabó G, Nunley KR, Hoffman PL. Antisense oligonucleotide to c-fos blocks the ability of arginine vasopressin to maintain ethanol tolerance. Eur J Pharmacol 1996; 306:67-72. [PMID: 8813616 DOI: 10.1016/0014-2999(96)00206-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Administration of the neuropeptide, arginine vasopressin, can reduce the rate of dissipation of functional ethanol tolerance in mice that have acquired that tolerance. We previously showed that intracerebroventricular vasopressin administration can also produce an increase in septal c-fos mRNA levels. To evaluate the role of the increased expression of c-fos in the ability of vasopressin to maintain tolerance, ethanol-tolerant mice were given intracerebroventricular injections of vasopressin in the presence or absence of an antisense oligonucleotide to c-fos. The antisense oligonucleotide completely blocked the ability of vasopressin to maintain ethanol tolerance, while a missense oligonucleotide was without effect. The antisense oligonucleotide also attenuated the increase in septal c-fos mRNA levels caused by vasopressin. The results provide evidence for a role of c-fos expression in the maintenance of ethanol tolerance by vasopressin.
Collapse
Affiliation(s)
- G Szabó
- Department of Pharmacology, University of Colorado Health Sciences Center, Denver 80262, USA
| | | | | |
Collapse
|
18
|
Zhang SP, Zhou LW, Morabito M, Lin RC, Weiss B. Uptake and distribution of fluorescein-labeled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain. J Mol Neurosci 1996; 7:13-28. [PMID: 8835779 DOI: 10.1007/bf02736845] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
To determine the uptake and distribution of oligodeoxynucleotides in brain, a 20-mer phosphorothioated oligodeoxynucleotide complementary to a portion of the D2 dopamine receptor mRNA was fluorescently labeled with fluorescein isothiocyanate (FITC) and injected into the lateral cerebral ventricles of mice. At various survival times after the injection, the brains were removed, fixed, sectioned, and viewed under a fluorescent microscope. The results showed that the oligodeoxynucleotide was rapidly taken up into the brain. Initially the label was relatively diffusely spread throughout the interstitial spaces of the brain, then became redistributed to the cellular compartments. The signal extended from those forebrain nuclei located immediately in contact with the ventricles, such as the corpus striatum, septum, and hippocampus, to areas further removed from the ventricles, such as the cerebral cortex, nucleus accumbens, and substantia nigra. When the FITC-labeled D2 antisense oligodeoxynucleotide was given once daily for 4 d, the signal intensity seen 24 h after the last injection appeared to be of greater intensity overall compared to that seen after a single injection. At early time-points the oligodeoxynucleotide signals appeared to be punctuated and were found in cell bodies as well as in proximal dendritic processes. However, not all cells were equally labeled, suggesting an uneven uptake and accumulation of the D2 antisense into the various cell types. At later time-points the fluorescent signal appeared granular; at these times the injected material was largely degraded. These studies show that a D2 dopamine receptor antisense oligodeoxynucleotide is rapidly taken up from cerebral ventricles into brain, becomes widely distributed throughout the brain tissue to areas far removed from direct contact with the ventricles, and appears to accumulate to a different extent in the various brain areas and cell types.
Collapse
Affiliation(s)
- S P Zhang
- Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, USA
| | | | | | | | | |
Collapse
|